On Thursday, Acting Attorney General Todd Blanche signed the order. State-licensed medical cannabis and FDA-approved cannabis products are now Schedule III controlled substances. After years of limbo, the federal government has formally acknowledged that cannabis has medical value. For cannabis operators, this distinction matters enormously—but probably not in the way the headlines suggest.

The immediate win is tax relief. Under Internal Revenue Code Section 280E, cannabis businesses have been barred from deducting ordinary business expenses—rent, payroll, utilities, and marketing. Schedule III status removes that barrier. For operators running on thin margins, this is structural relief, not symbolic. Trulieve CEO Kim Rivers put it plainly: "The Administration is delivering on its promise to address long overdue cannabis reform by rescheduling medical marijuana. President Trump and Attorney General Blanche have delivered on the promise."

Research access loosens substantially. Schedule III drugs face fewer regulatory hurdles for clinical study than Schedule I substances. Universities and private labs can now pursue cannabis research without the federal friction that made the past decade nearly impossible. This opens pathways for standardized dosing data, safety profiles, and efficacy studies that the industry has desperately needed.

Risk perception matters. Banks and institutional investors have treated cannabis like radioactive material because of Schedule I status. Reclassification signals that the federal government no longer views cannabis as a substance with no medical value. That's not the same as banks rushing to open accounts—but it's a psychological and political shift. Mark Lewis, President of Specialty Payments at Lüt, calls it "the single most important drug policy move in decades" for research and patient access. But he's also blunt about what it doesn't do: "The biggest misconception is that rescheduling suddenly normalizes the business of cannabis. The financial system doesn't move at the speed of a headline. Banks, card networks and regulators are still reacting to risk, and when risk is unclear, their default is to pull back, not lean in."

State licensing frameworks remain untouched. Your state regulates your business today. Schedule III rescheduling doesn't alter that. Illinois operators still operate under Illinois rules. Colorado still enforces Colorado law. The DEA didn't become your licensor.

Interstate commerce stays illegal for non-FDA products. Schedule III status does permit interstate movement of FDA-approved drugs—think Marinol and Epidiolex. But the flower and concentrates you sell in your dispensary? Still confined to state lines. The mythical "interstate commerce opportunity" remains mythical unless your products complete FDA approval as prescription medications. That's a pharmaceutical pathway, not a regulatory one.

Banking access does not improve overnight. Rescheduling does not create new banking authority or remove the compliance burden that makes cannabis toxic for financial institutions. The SAFER Banking Act—which would actually protect banks serving cannabis businesses—remains stalled in Congress. Rescheduling improves the political environment for SAFER Banking to pass, but it doesn't pass it.

Federal prohibition remains intact. Cannabis is still a controlled substance. Possession arrests for recreational use don't stop. State-legal adult-use operators face legal ambiguity: the order covers medical cannabis and FDA-approved products, but recreational businesses exist in a regulatory gray zone pending the next hearing.

The real fight moves to Congress. An expedited administrative hearing begins June 29, 2026, to evaluate broader rescheduling beyond medical and FDA-approved products. That hearing could recommend full descheduling or broader Schedule III status. But Congress ultimately controls whether SAFER Banking passes, whether the 280E fix becomes permanent, and whether the state-federal conflict gets resolved.

Industry leadership acknowledges the incremental nature of the win. The National Cannabis Industry Association stated plainly: "Rescheduling, while hailed as an incremental win for the legal cannabis industry, would not legalize marijuana or harmonize federal law with the laws that allow for either medical or adult-use cannabis sales in 38 states."

For operators, the message is clear: this is progress, not a finish line. Your compliance standards don't relax. Your state licensing doesn't change. But your tax burden just got lighter, your research opportunities just expanded, and the political momentum behind broader reform just accelerated. Don't confuse relief with normalization.